Gynecologic Oncology May Face a Future of Too Few Cases, Too Many Docs Subspecialists could see only one patient a week with a new cancer diagnosis, researcher says Mar 18, 2024
Raludotatug Deruxtecan Promising in Platinum-Resistant Advanced Ovarian Cancer Novel ADC targeting CDH6 achieves response in nearly 50% of patients Mar 17, 2024
Cancer Prevention Strategies Linked to Mortality Reduction in BRCA Carriers Cohort studies indicate oophorectomy, breast MRI surveillance save lives, researchers say Feb 29, 2024
Two-Stage Screening Strategy for Ovarian Cancer Continues to Show Progress Large study shows stage shift, high specificity, increasing PPV over 21 years Jan 24, 2024
Early Detection Is Key to Higher Cure Rates in Ovarian Cancer "We are not aware of precancer stages for ovarian cancer" Dec 13, 2023
Cancer Patient's Final Act: Destroying Medical Debt Viral campaign will erase some $60 million in medical debt Nov 22, 2023
Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer Alone or combined with a PD-1 inhibitor, ubamatamab showed promise in phase I trial Nov 09, 2023
T-DXd Tied to Encouraging Survival in HER2-Expressing Gyn Cancers More responses, longer OS in subset with the highest levels of HER2 expression Nov 07, 2023
RAF/MEK and FAK Inhibitor Combo Effective in Low-Grade Serous Ovarian Cancer Impressive overall response rate with avutometinib-defactinib in RAMP 201 trial Nov 05, 2023
In BRCA Breast Cancer, Prophylactic Salpingo-Oophorectomy Tied to Better Survival PSO should be performed early, particularly for those with the BRCA1 variant, researchers say Oct 04, 2023
Preoperative Algorithm Might Halve Unnecessary Oophorectomies in Children Researchers point to potential for reduction in lifelong consequences Oct 03, 2023
Is Being a Night Owl Unhealthy? CRC Screening Not Recommended Enough Also in TTHealthWatch: CVD death and obesity Sep 16, 2023 podcast
How the Chemotherapy Shortage Is Affecting Frontline Clinicians "How are we here in 2023 having some of these discussions?" bemoans gynecologic cancer expert Sep 08, 2023 video
New Ovarian Cancer Drug Extends Survival in Resistant Disease "Practice changing" findings for tough-to-treat patient population Jun 04, 2023
Pricey Drug Combo Boosts PFS in First-Line Advanced Ovarian Cancer Questions about anti-PD-L1 contribution, cost, and access to durvalumab, bevacizumab, olaparib Jun 03, 2023
Many With Cancer Predisposition Diseases Unaware of Genetic Status Moreover, a significant proportion do not qualify for genetic screening under current guidelines Apr 19, 2023
Risks Outweigh Benefits for BSO at Benign Hysterectomy in Younger Women It's less clear-cut for postmenopausal women, study authors say Apr 18, 2023
VTE Risk in Recurrent Ovarian Cancer Increases With More Lines of Chemotherapy Prospective study in heavily treated population is warranted, researcher says Mar 30, 2023
Novel Strategies Show Winning Potential in Ovarian Cancer High response rates in small studies of immuno-oncology combination, neoadjuvant olaparib Mar 28, 2023
CDK4/6 Inhibition Active in Recurrent Low-Grade Serous Ovarian Cancer Responses in a fourth of patients, clinical benefit in up to 90% Mar 26, 2023
OS Benefit Eludes Second-Line Niraparib Maintenance in Ovarian Cancer Significant PFS results demonstrated in NORA trial don't extend to overall survival Dec 17, 2022
FDA OKs First Antibody-Drug Conjugate for Platinum-Resistant Ovarian Cancer Mirvetuximab soravtansine produced responses in almost a third of patients in pivotal trial Nov 15, 2022
Pandemic Led to Surgical Delays in Gynecologic Cancers, and Worse Outcomes One in five patients experienced changes in their care plan Oct 04, 2022
Rucaparib a Winner for PFS, But Not for OS, in Recurrent Ovarian Cancer PARP inhibitor still has value as maintenance therapy, ARIEL3 investigator says Oct 01, 2022
'Potential Detrimental Effect' With Fourth-Line Olaparib in Ovarian Cancer Post-hoc data from SOLO3 show diverging results based on prior lines of therapy Sep 30, 2022
Maintenance PARP Inhibition Boosts OS in Two Ovarian Cancer Trials Results from SOLO-1 and PAOLA-1 show "clinically meaningful" long-term results with olaparib Sep 09, 2022
Does PARP Inhibitor Maintenance Induce Platinum Resistance in Ovarian Cancer? Shorter progression-free interval with platinum chemotherapy after olaparib maintenance Sep 01, 2022
Nonselective Beta-Blockers May Improve Outcomes in Ovarian Cancer Lower all-cause, cancer-specific mortality in women who received the drugs around time of surgery Aug 29, 2022
Two Sides of Endosalpingiosis: Benign Growth or Harbinger of Cancer? Concurrent malignancy more than twice as common as compared with endometriosis, study showed Aug 06, 2022
Prosthetic Mesh May Stand in the Way of Further Abdominal Operations Prior incisional hernia repair associated with complications with later abdominal surgery Aug 04, 2022
Another Possible Use for Aspirin: Reducing Ovarian Cancer Risk Potential benefit seen in women with and without established cancer risk factors Jul 27, 2022
Drugmaker Pulls Third-Line PARP Inhibitor Approval in Ovarian Cancer Decision on rucaparib follows negative OS signal and "discussions" with FDA Jun 17, 2022
PARP Inhibitor Picks Up a Win in Frontline Maintenance for Ovarian Cancer Median PFS more than doubled with rucaparib after response to platinum-based chemotherapy Jun 07, 2022
IL-15 Agonist Impresses in Non-Muscle Invasive Bladder Cancer High response rate, 99%-100% cancer-specific survival at 2 years Jun 04, 2022
New Clue to Risk of Peritoneal Cancer After Prophylactic Salpingo-Oophorectomy Women with BRCA variant and serous tubal intraepithelial carcinoma had a 34-fold greater risk Apr 05, 2022
Intraperitoneal Carboplatin Boosts PFS in Ovarian Cancer Should the gynecologic oncology community reconsider IP therapy? Mar 22, 2022
Novel ADC Promising in Tough-to-Treat Ovarian Cancer Ocular AEs an issue with mirvetuximab in folate receptor alpha-high platinum-resistant disease Mar 20, 2022
Adjuvant Chemo Disappoints in Low-Grade Serous Ovarian Cancer Study suggests no improvement in overall survival Mar 19, 2022
Uterine Cancer Mortality Now Neck and Neck With Ovarian Cancer Advances in ovarian cancer, stagnation in uterine cancer, and "alarming" racial disparity Feb 09, 2022
A Better Option for Preserving Fertility in Gynecologic Cancer Patients? In vitro maturation can result in both embryos and oocyte vitrification, researcher says Oct 19, 2021
